         |
April 26 |
|
| 8:00 a.m. - 8:15 a.m. | Poster Set Up (Day 1 Posters) |
| 8:15 a.m. - 8:30 a.m. | Welcome and Plenary Introduction Robert Yarchoan Office of HIV and AIDS Malignancy National Cancer Institute, NIH, USA |
| 8:30 a.m. - 9:00 a.m. | HPV Vaccination in HIV-Positive Men and Women- Challenges and Opportunities Joel Palefsky University of California, San Francisco, USA |
| 9:00 a.m. - 10:30 a.m. | Session 1: Cervical Cancer Control in Developing Countries Moderators: Joe Harford National Cancer Institute, NIH, USA Joel Palefsky |
| 9:00 a.m. - 9:30 a.m. | Cervical Cancer Control in Developing Countries: Impact of HIV Infection Rengaswamy Sankaranarayanan International Agency for Research on Cancer, France |
| 9:30 a.m. - 10:00 a.m. | A Population-Based Study of Point-of-Care HPV Testing, Visual Inspection with Acetic Acid, and Cervical Cytology in Rwandan Women of Known HIV-Serostatus Eugene Mutimura Women's Equity in Access to Care and Treatment, Rwanda |
| 9:45 a.m. - 10:00 a.m. | CIRDZ/UAB Cervical Cancer Prevention Program in Zambia Groesbeck P. Parham University of Alabama, USA |
| 10:00 a.m. - 10:30 a.m. | Factors Impacting Introduction of HPV Vaccination in Low Resource Settings Aisha Jumaan, PATH, USA |
| 10:15 a.m. - 10:30 a.m. | Questions and answers (directed at all speakers) |
| 10:30 a.m. - 11:00 a.m. | Break: Coffee and Poster Viewing |
| 11:00 a.m. - 12:30 p.m. | Session 2: KSHV Biology
Moderators: Denise Whitby Dirk Dittmer |
| 11:00 a.m. - 11:30 a.m. | B cellInfection by KSHV and its Control by T Cells Don Ganem University of California, San Francisco, USA |
| 11:30 a.m. - 11:45 a.m. | Bim nuclear translocation and inactivation by HHV-8 interferon regulatory factor 1 John Nicholas Johns Hopkins University School of Medicine, USA |
| 11:45 a.m. - 12 noon | Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma Utthara Nayar Weill Cornell Medical College, USA |
| 12 noon - 12:15 p.m. | Upregulation Angiopoietin-like 4 by viral G Protein-coupled Receptor Promotes Angiogenesis and Vascular Permeability in Kaposi's sarcoma Silvia Montaner University of Maryland, USA |
| 12:15 p.m. - 12:30 p.m. | KSHV regulation of fibulins in Kaposi's sarcoma: Implications for tumorigenesis Donald Alcendor Meharry Medical College, USA |
| 12:30 p.m. - 1:00 p.m. | Lunch (lunch on your own) or pre-bought lunch box |
| 1:00 p.m. - 2:00 p.m. | Poster Viewing (Presenters stand by posters) |
| 2:00 p.m. - 3:30 p.m. | Session 3: New and Old Viruses-Impact on Chronic Diseases Moderators:C. David Pauza Institute of Human Virology Kishor Bhatia |
| 2:00 p.m. - 2:30 p.m. | Pathogenic Consequences of Xenotropic Murine Virus-related Virus (XMRV) Expression in the Development of Chronic Diseases Frank Ruscetti National Cancer Institute, NIH, USA |
| 2:30 p.m. - 3:00 p.m. | Merkel Cell Polyomavirus and Two Novel Polyomaviruses Are Chronically Shed from Human Skin Christoper Buck National Cancer Institute, NIH, USA |
| 3:00 p.m. - 3:15 p.m. | HIV-associated Salivary Gland Disease: A Role for BK Virus Liesl K. Jeffers University of North Carolina at Chapel Hill, USA |
| 3:15 p.m. - 3:30 p.m. | Bacteria mediated reactivation of Gammaherpesviruses Jennifer Webster-Cyriaque University of North Carolina at Chapel Hill, USA |
| 3:30 p.m. - 5:30 p.m. | Break: Coffee and Poster Viewing |
| 4:00 p.m. - 5:15 p.m. | Session 4: Clinical Trials Data in HIV/AIDS-Associated Malignancies Moderators: Alexandra Levine City of Hope National Medical Center, USA Richard Little |
| 4:00 p.m. - 4:15 p.m. | Phase II AIDS Malignancy Consortium (AMC) trial of Imatinib in AIDS-associated Kaposi's sarcoma (KS) Henry B. Koon Case Western Reserve University, USA |
| 4:15 p.m. - 4:30 p.m. | Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-associated Herpes Virus (KSHV) associated Multicentric Castleman Disease (MCD) Thomas Uldrick National Cancer Institute, NIH, USA |
| 4:30 p.m. - 4:45 p.m. | The KAART Trial: A randomised controlled trial of HAART compared to the combination of HAART and chemotherapy in treatment naïve patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa Thomas Uldrick National Cancer Institute, NIH, USA |
| 4:45 p.m. - 5:00 p.m. | Distinct Profiles of Antibodies to Kaposi Sarcoma-Associated Herpesvirus Antigens in Patients with Kaposi Sarcoma, Multicentric Castlemen's Disease, and Primary Effusion Lymphoma Peter D. Burbelo National Institute of Dental and Craniofacial Research, NIH, USA |
| 5:00 p.m. - 5:15 p.m. | Pooled analysis of aids-malignancy consorTium (AMC) trials evaluating rituximab plus either chop or infusional epoch chemotherapy in Hiv-associated Non-Hodgkin's lymphoma Stefan K. Barta Montefiore-Einstein Cancer Center, USA |
| 5:15 p.m. | End of Day One |
April 27 |
|
| 8:00 a.m. - 8:15 a.m. | Poster Set Up (Day 2 Posters) |
| 8:15 a.m. - 8:25 a.m. | Opening Comments Geraldina Dominguez National Cancer Institute, NIH, USA |
| 8:25 a.m. - 8:30 a.m. | Plenary Introduction Eric Engels National Cancer Institute, NIH, USA |
| 8:30 a.m. - 9:00 a.m. | Epidemiology of HIV-Associated Cancers: New Findings from the Long-Term Follow-Up of Cohorts on HAART Gary Clifford International Agency for Research on Cancer, France |
| 9:00 a.m. - 10:00 a.m. | Session 5: Epidemiology of HPV-Associated Cancers Moderators: John Brooks Centers for Disease Control and Prevention Eric Engels |
| 9:00 a.m. - 9:15 a.m. | Cervical cancer epidemiology among HIV-infected women in North America Gypsyamber D'Souza Johns Hopkins Bloomberg School of Public Health, USA |
| 9:15 a.m.- - 9:30 a.m. | Progression of Cervical Neoplasia in HIV Seropositive Women with and without Antiretroviral Therapy in Johannesburg, South Africa Cynthia Firnhaber University of Witwatersrand, Johannesburg, South Africa |
| 9:30 a.m. - 9:45 a.m. | Persistence of anal squamous intraepithelial lesions and anal HPV infection in HIV-infected patients despite immune restoration under cART Christophe Piketty Hôpital Européen Georges Pompidou, Paris, France |
| 9:45 a.m. - 10:00 a.m. | Risk of anal cancer in HIV-Infected patients and HIV-uninfected controls in North America Michael J. Silverberg Kaiser Permanente Northern California, USA |
| 10:00 a.m. - 10:30 a.m. | Break: Coffee and Poster Viewing |
| 10:30 a.m. - 11:00 a.m. | Plenary Introduction Sam Mbulaiteye National Cancer Institute, NIH, USA HIV and Cancer among Children in Africa |
| 11:00 a.m. - 12 noon | Session 6: International Partnerships Moderators: Corey Casper Fred Hutchinson Cancer Research Center, USA Sam Mbulaiteye |
| 11:00 a.m. - 11:15 a.m. | Integrative proteomics and genomics supports a role for interferon gamma in the pathogenesis of Kaposi Sarcoma and finds multiple candidate diagnostic proteins for early detection or prevention Lynn Amon Fred Hutchinson Cancer Research Center, USA |
| 11:15 a.m. - 11:30 a.m. | Malignant lymphoma incidence and HIV-related lymphoma subtypes in the Western Cape of South Africa, 2002-2009 Leona Ayers Ohio State University, USA |
| 11:30 a.m. - 11:45 a.m. | HPV Genotype and EGFR Activation in Conjunctival Carcinoma Among HIV Patients in East Africa Scot C. Remick West Virginia University, USA |
| 11:45 a.m. - 12 noon | Visual inspection and HPV-based cervical cancer screening for HIV-infected women in Pune, India Vikrant Sahasrabuddhe Vanderbilt University, USA |
| 12 noon - 12:30 p.m. | Lunch (lunch on your own) or pre-bought lunch box |
| 12:30 p.m. - 1:30 p.m. | Poster Viewing (Presenters stand by posters) |
| 1:30 p.m. - 3:00 p.m. | Session 7: EBV Biology and Lymphomagenesis Moderators: Elliot Kieff Harvard Medical School, USA Ethel Cesarman |
| 1:30 p.m. - 2:00 p.m. | Epigenetic and Transcriptional Programming and Therapy in B-Cell Lymphomas Ari Melnick Weill Cornell Medical College, USA |
| 2:00 p.m. - 2:15 p.m. | An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells Mica Luftig Duke University School of Medicine, USA |
| 2:15 p.m. - 2:30 p.m. | TNFAIP3(A20) genetic alterations in AIDS related lymphomas Lisa Giulino New York Presbyterian Hospital, Well Cornell Medical College, USA |
| 2:30 p.m. - 2:45 p.m. | C/EBPbeta mediates bortezomib-induced EBV and KSHV lytic gene expression Courtney O'Farrell Johns Hopkins School of Medicine, USA |
| 2:45 p.m. - 3:00 p.m. | Elevated serum levels of CXCL13 precede HIV-associated non Hodgkin's lymphoma Shehnaz K. Hussain University of California, Los Angeles, USA |
| 3:00 p.m. - 3:30 p.m. | Break: Coffee and Poster Viewing |
| 3:30 p.m. - 4:45 p.m. | Session 8: Cancers in the Era of Combination Antiretroviral Therapy Moderators: Richard Ambinder Johns Hopkins School of Medicine, USA Joseph Sparano |
| 3:30 p.m. 3:45 p.m. | Decreased risk of breast cancer associated with X4-tropic HIV Nancy A. Hessol University of California, San Francisco, USA |
| 3:45 p.m. - 4:00 p.m. | HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence, outcome and evolution of CD4+ T cell lymphocytes Matthias Egger Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland |
| 4:00 p.m. - 4:15 p.m. | Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy Emilie Lanoy INSERM, Paris, France |
